Alana Hippensteele, Managing Editor from Pharmacy Times - Journalist Profile

	Profile	Contacts	Recent Articles on Subject
1	Alana Hippensteele, Managing Editor Pharmacy Times		Use of Recurrence Score Combined With Clinical, Genetic Factors Improves Prognostic Ability in HR+/ HER2– Early Breast Cancer - 5 months ago MAPS PBC Submits NDA to the FDA for MDMA-Assisted Therapy for PTSD - 5 months ago Subcutaneous Daratumumab Plus VRd Significantly Improved PFS, Increased Depth of Response in Patients With Newly Diagnosed Multiple Myeloma - 5 months ago AI Model Can Differentiate Prefibrotic Primary Myelofibrosis From Essential Thrombocythemia With High Accuracy - 5 months ago Ibrutinib Plus Venetoclax With MRD-Directed Duration of Treatment Is a New Standard of Care Regimen for Previously Untreated CLL - 5 months ago Gender Gap in NIH-Awarded Research Grants Persists in the Field of Non-Malignant Hematology - 5 months ago Assessing Clinical Trial Efficacy vs Real-World Effectiveness in the Treatment of Multiple Myeloma - 5 months ago Prenatal Folate May Program Hematopoietic Stem Cell Function Into Adulthood - 5 months ago Current Trends, Treatment Strategies for C diff Infection - 6 months ago Abelacimab Demonstrates Significant Reduction in Bleeding vs Rivaroxaban in Patients With Atrial Fibrillation - 6 months ago Data Show Effect of Dietary Sodium Reduction on Blood Pressure Was Comparable to First-Line Medication - 6 months ago Data Show Lepodisiran Was Well Tolerated, Substantially Lowered Lipoprotein (a) - 6 months ago Data Show Benefit of Intensive Blood Pressure Reduction Is Consistent in East Asian Population With Hypertension, High Cardiovascular Risk - 6 months ago SELECT Trial Data Show Benefit of Semaglutide in Patients With Obesity - 6 months ago Cardiovascular-Kidney-Metabolic Syndrome Requires a Collaborative Approach to Treatment - 6 months ago Hyperkalemia Recurrence in Patients With CKD Contributes to Increased Health Care Resource Utilization, Cost - 7 months ago Patients With CKD, Hyperkalemia Have Higher Rates of Major Adverse Cardiovascular Events - 7 months ago Phase 3 Study Supports Pembrolizumab Plus Lenvatinib as Standard of Care in Patients With Advanced Endometrial Cancer Who Received Prior Platinum Therapy - 7 months ago Oncology Pharmacists “Approve Every Regimen That Gets Built Into the Oncology EMR,” yet Pharma Often Overlooks Their Role - 7 months ago